Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPR65 agonist (OMass Therapeutics)
- Development stage
- Preclinical
- Lead developer
- OMass Therapeutics
- Modality
- Small Molecules
01
Overview
OMass Therapeutics is developing a first-in-class small molecule agonist of GPR65 for the treatment of inflammatory bowel disease (IBD). GPR65 is a pH-sensing G protein-coupled receptor (GPCR) primarily expressed on immune cells. By activating GPR65, the therapy aims to reduce pro-inflammatory cytokines, increase pro-resolution cytokines, and enhance epithelial barrier repair. The program, discovered using the proprietary OdyssION platform, was licensed to Genentech (Roche) in September 2025 for further development.
- Other names
- GPR65 programGPR-65 programGPR 65 program
02
Targets
GPR65 (G protein-coupled receptor 65)
Beyond the preview
Go deeper on GPR65 agonist (OMass Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPR65 agonist (OMass Therapeutics).